Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine for the prevention of genital warts in males: profile report. firstname.lastname@example.org.
Bottom Line: †Adapted and reproduced from the original article published in Drugs 2011; 71 (5): 591-602..
Affiliation: Adis, Auckland, New Zealand.
†Adapted and reproduced from the original article published in Drugs 2011; 71 (5): 591-602..
Related in: MedlinePlus
Mentions: The quadrivalent HPV types 6, 11, 16, 18 vaccine (Gardasil®; hereafter referred to as the quadrivalent HPV vaccine) is a noninfectious recombinant vaccine and comprises purified virus-like particles derived from the L1 capsid proteins of HPV types 6, 11, 16, and 18. Each dose contains approximately 20, 40, 40, and 20 µg of each virus-like particle type, respectively, and includes 225 µg of amorphous aluminium hydroxyphosphate sulfate adjuvant (AAHS). It was approved in females in the US in 2006 for the prevention of various diseases caused by HPV types 6, 11, 16, and 18, and has recently been approved in males for the prevention of genital warts caused by HPV types 6 and 11. Over 61 million doses of the quadrivalent HPV vaccine have been distributed worldwide. The features and properties of the quadrivalent HPV vaccine are presented in table I.Table I